Biofrontera (BFRI) Stock Analysis & Winston Score

Biofrontera is a small pharmaceutical company that sells prescription drugs used to treat skin conditions. Its main product is Ameluz, a cream used alongside a special light treatment called photodynamic therapy (PDT) to treat actinic keratosis — rough, scaly patches on the skin caused by sun damage that can turn into skin cancer. Doctors, dermatologists, and skin care clinics are the primary customers. The company makes money by selling Ameluz directly to healthcare providers in the United States, which is its core market. Biofrontera licenses the drug from a German company called Biofrontera AG, which developed it, making Biofrontera Inc. essentially the U.S. commercial arm of that product. Its high gross margin of around 83% reflects the typical pricing power of specialty prescription drugs, but the company is still losing money at the operating level, meaning it spends more on sales and overhead than it earns in profit. The key risk is its dependence on a single product in a competitive dermatology market where larger companies have broader resources.